Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in CVS Health Corporation $CVS

Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of CVS Health Corporation (NYSE:CVS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 3,118,927 shares of the pharmacy operator’s stock, valued at approximately $322,653,000. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.24% of CVS Health as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of CVS. Handelsbanken Fonder AB grew its stake in CVS Health by 83.6% in the second quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after acquiring an additional 496,124 shares during the period. State Street Corp raised its position in shares of CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Legal & General Group Plc lifted its holdings in shares of CVS Health by 0.3% in the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock worth $738,777,000 after purchasing an additional 31,249 shares in the last quarter. Deutsche Bank AG grew its position in CVS Health by 28.4% in the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock valued at $370,333,000 after purchasing an additional 1,031,998 shares during the period. Finally, Hussman Strategic Advisors Inc. bought a new stake in CVS Health during the 4th quarter valued at $3,333,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

NYSE CVS opened at $93.99 on Tuesday. The company has a fifty day moving average price of $102.46 and a 200-day moving average price of $88.41. The firm has a market cap of $120.21 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 0.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1 year low of $69.40 and a 1 year high of $110.68.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period last year, the firm earned $1.81 earnings per share. The firm’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s payout ratio is presently 70.37%.

Insider Activity

In other news, Director Larry Robbins sold 1,018,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00. Following the completion of the transaction, the director directly owned 5,195,261 shares of the company’s stock, valued at $487,419,387.02. This represents a 16.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. DA Davidson upped their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Cantor Fitzgerald raised their price target on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Bank of America lifted their price target on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Finally, HSBC reissued a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.75.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.